Compare CBIO & MTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | MTW |
|---|---|---|
| Founded | 2003 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Construction/Ag Equipment/Trucks |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.5M | 498.8M |
| IPO Year | 2013 | 1994 |
| Metric | CBIO | MTW |
|---|---|---|
| Price | $17.14 | $20.68 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 4 |
| Target Price | ★ $26.67 | $10.50 |
| AVG Volume (30 Days) | 283.5K | ★ 321.1K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | $18,500.00 | ★ $2,240,900,000.00 |
| Revenue This Year | N/A | $4.73 |
| Revenue Next Year | $279.20 | $2.98 |
| P/E Ratio | ★ N/A | $94.86 |
| Revenue Growth | N/A | ★ 2.89 |
| 52 Week Low | $8.72 | $9.15 |
| 52 Week High | $27.41 | $20.92 |
| Indicator | CBIO | MTW |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 82.54 |
| Support Level | $17.02 | $11.68 |
| Resistance Level | $17.80 | N/A |
| Average True Range (ATR) | 1.12 | 0.81 |
| MACD | 0.21 | 0.67 |
| Stochastic Oscillator | 83.78 | 90.57 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.